Subscribe

Ovarian Cancer

PAOLA-1: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

The addition of maintenance olaparib with bevacizumab significantly improves progression-free survival, especially in patients with HRD-positive tumors, including those without a BRCA mutation.

MITO-7: Weekly chemotherapy in ovarian cancer

Weekly chemotherapy vs. q3 weekly chemotherapy in advanced ovarian cancer

GOG 281: Trametinib in recurrent low-grade serous ovarian cancer

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer.

MIRASOL: Mirvetuximab in Platinum Resistant Cancer

Mirvetuximab Soravtansine (MIRV) in platinum resistant ovarian cancer

Immunotherapy in Ovarian Cancer

Recent trials in Ovarian Cancer and Immunotherapy

DESTINY-PanTumor02

Phase II study evaluating the role of HER2-directed ADC Trastuzumab deruxtecan (T-DxD)

Surgical technique for Risk Reduction Salpingo-oophorectomy

Do you perform RRSO? What is your technique

Venous Thromboembolism Prevention in Ovarian Cancer

VTE prophylaxis from the start of NACT to the end of treatment can reduce VTE rates by 80%